April 18, 2008 - Boston Scientific Corpo. has received approval for the sale of its TAXUS Liberte paclitaxel-eluting coronary stent system in Canada, which it plans to launch the product immediately in Canada.
The Company reported that Health Canada's Therapeutic Products Directorate (TPD), the authority that regulates pharmaceutical drugs and medical devices, has approved its use.
